SMI 11’817 -1.0%  SPI 15’339 -1.0%  Dow 34’798 0.1%  DAX 15’532 -0.7%  Euro 1.0824 -0.1%  EStoxx50 4’159 -0.9%  Gold 1’750 0.4%  Bitcoin 39’725 -4.3%  Dollar 0.9257 0.2%  Öl 78.0 1.0% 

Incyte Aktie 134791 / US45337C1027

67.25
CHF
-31.80
CHF
-32.11%
18:00:00
BRX

Aktionärsstruktur

Inhaber in %
Freefloat 99.11
Baker Bros. Advisors LP 14.73
Baker Bros. Advisors LP 14.50
T. Rowe Price Associates, Inc. (Investment Management) 12.94
T. Rowe Price Associates, Inc. (Investment Management) 10.80
Vanguard Group, Inc. (Subfiler) 8.91
Dodge & Cox 6.16
Wellington Management Co. LLP 5.28
Vanguard Health Care Fund 4.08
Dodge & Cox Stock Fund 3.83
State Street Corp. 3.82
BlackRock Fund Advisors 3.61
Vanguard Total Stock Market Index Fund 2.39
Renaissance Technologies LLC 2.04
Sands Capital Management LLC 1.93

*Die Summe der Anteile kann 100% überschreiten, da bestimmte Anteilseigner zum Freefloat dazu gerechnet wurden.

Personal

2016 2017 2018 2019 2020
Personal am Ende des Jahres 980 1’208 1’367 1’456 1’773
Umsatz pro Mitarbeiter in Mio. EUR 1.13 1.27 1.38 1.48 1.50

Bilanz (in Mio. EUR) - Aktiva

2016 2017 2018 2019 2020
Summe Umlaufvermögen 994 1’505 1’832 2’481 2’360
Summe Anlagevermögen 1’071 1’655 1’943 2’670 2’673
Summe Aktiva 1’639 2’303 2’646 3’427 3’584

Bilanz (in Mio. EUR) - Passiva

2016 2017 2018 2019 2020
Gesamtverschuldung/ -verbindlichkeiten 651 24 17 72 62
Summe Fremdkapital 1’219 672 720 828 972
Summe Eigenkapital 419 1’631 1’926 2’598 2’611
Summe Passiva 1’639 2’303 2’646 3’427 3’584

Adresse

1801 Augustine Cut-Off, 19803 Wilmington
Telefon +1 (302) 498-6700
URL http://www.incyte.com

Management

Barry Flannelly
Executive Vice President & General Manager
Christiana Stamoulis
Chief Financial Officer & Executive Vice President
Dashyant Dhanak
Chief Scientific Officer & Executive VP
Edmund P. Harrigan
Independent Director
Herve Hoppenot
Chairman, President & Chief Executive Officer
Holly Koblish
Senior Director-Pharmacology
Jacqualyn A. Fouse
Independent Director
Jean-Jacques Bienaimé
Independent Director
Julian Charles Baker
Lead Independent Director
Katherine A. High
Independent Director
Keith Mikkelson
Executive Director-Business Development
Lauren Ayala
Senior Director-Investor Relations
Lothar H. Finke
Head-Clinical Development & General Manager-Japan
Maria E. Pasquale
Secretary, Executive VP & General Counsel
Michael Charles A. Booth
Division Vice President-Investor Relations
Michael Morrissey
Executive VP & Head-Global Technical Operations
Paul J. Clancy
Independent Director
Paul Trower
Principal Accounting Officer & VP-Finance
Paula J. Swain
Executive Vice President-Human Resources
Peter Langmuir
Vice President-Oncology Drug Development
Phillip Liu
Associate Director-Applied Technology
Robert Newton
Vice President-Drug Discovery Biology
Steven H. Stein
Chief Medical Officer & Executive Vice President
Vijay Iyengar
EVP-Global Strategy & Corporate Development
Wendy L. Dixon
Independent Director
Wenqing Yao
Executive Vice President-Discovery Chemistry

Eintrag hinzufügen

Erfolgreich hinzugefügt!. Zu Portfolio/Watchlist wechseln.

Es ist ein Fehler aufgetreten!

Kein Portfolio vorhanden. Bitte zusätzlich den Namen des neuen Portfolios angeben. Keine Watchlisten vorhanden. Bitte zusätzlich den Namen der neuen Watchlist angeben.

CHF
Hinzufügen